SutroVax lands another $100M+ in upstart quest against Pfizer’s blockbuster Prevnar 13
For the last half-decade, in a facility just south of South San Francisco, the spinoff of a small Stanford spinout has been quietly gunning for Pfizer and the world’s most lucrative vaccine market. Now, they say they’re ready (almost).
SutroVax announced a $110 million Series D financing that will help take the company and its rival to Pfizer’s blockbuster pneumococcal vaccine Prevnar 13 into the clinic, although not until 2021. Having slowly amassed a long list of A-list investors since their J&J-backed 2013 launch, the biotech added RA Capital Management and Janus Henderson Investors this round to go along with all their institutional backers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.